Literature DB >> 32158198

Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life.

Suein Choi1,2, Sangil Jeon3, Dong-Seok Yim1,2, Seunghoon Han1,2.   

Abstract

PURPOSE: The performance of "trough sampling before reaching steady-state" and "serial sampling beyond the interval between steady-state" in a multiple-dose pharmacokinetic evaluation was compared. Drugs with long half-lives, following multi-compartment pharmacokinetics, and whose distribution-related characteristics are less likely to be assessed within one dosing interval are focused. PATIENTS AND METHODS: Amlodipine pharmacokinetic data were collected from a human pharmacology study performed in Seoul St. Mary's Hospital (Seoul, Korea). Plasma concentration data until 144 hrs after a single administration was used. Nonlinear mixed-effects modeling was conducted to obtain the "true" model structure and pharmacokinetic parameter estimates. Then, stochastic simulation and estimation were performed using multiple-dose scenarios in various sampling strategies. Parameter accuracy and precision from each scenario were evaluated.
RESULTS: A two-compartment model with first-order absorption followed by zero-order absorption with a lag time then first-order elimination was chosen as the final model and used in the stochastic simulation and estimation. In terms of parameter precision, the scenario incorporating data only within one dosing interval showed the worst results (V p /F = 313%, Q/F = 64.3%). Some scenarios including early trough samples yielded comparable outcomes (V p /F = 18.4%, Q/F = 32.1%) to the extended full-PK sampling scenario (V p /F = 15.9%, Q/F = 30.3%), which was the best case. The quality of distribution-related parameters was the major difference between scenarios.
CONCLUSION: In multiple-dose studies on drugs with delayed distributional equilibrium, information from a few trough samples can augment the limit of serial sampling within the dosing interval for parameter estimation. With informative trough samples, extended hospitalization for serial sampling (until 3-5 half-lives after the last dose), which is particularly problematic for long half-life drugs, may be avoided. Trough samples obtained at the beginning of the repeated dose were more effective for mixed-effects modeling.
© 2020 Choi et al.

Entities:  

Keywords:  NONMEM; multiple-dose; pharmacokinetics; stochastic simulation and estimation; trough sampling

Mesh:

Substances:

Year:  2020        PMID: 32158198      PMCID: PMC7049277          DOI: 10.2147/DDDT.S236701

Source DB:  PubMed          Journal:  Drug Des Devel Ther        ISSN: 1177-8881            Impact factor:   4.162


  12 in total

1.  Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects.

Authors:  Jingli Duan; Jin Chen; Qi Yin; Rajesh Karan; Karin Meiser; Harold Tom Smith; Gangadhar Sunkara
Journal:  Int J Clin Pharmacol Ther       Date:  2012-01       Impact factor: 1.366

2.  Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.

Authors:  Christophe Schmitt; Agnès Portron; Shirin Jadidi; Neena Sarkar; Richard DiMarchi
Journal:  Diabetes Obes Metab       Date:  2017-07-20       Impact factor: 6.577

3.  Finding Tmax and Cmax in Multicompartmental Models.

Authors:  Yi Rang Han; Ping I Lee; K Sandy Pang
Journal:  Drug Metab Dispos       Date:  2018-08-22       Impact factor: 3.922

4.  Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.

Authors:  Xu Steven Xu; Min Yuan; Mats O Karlsson; Adrian Dunne; Partha Nandy; An Vermeulen
Journal:  AAPS J       Date:  2012-09-20       Impact factor: 4.009

5.  Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.

Authors:  David Ternant; Christophe Passot; Alexandre Aubourg; Philippe Goupille; Céline Desvignes; Laurence Picon; Thierry Lecomte; Denis Mulleman; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

6.  Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study.

Authors:  Chih-Wei Lin; Sandeep Dutta; Armen Asatryan; Haoyu Wang; Jack Clifton; Andrew Campbell; Wei Liu
Journal:  Clin Pharmacol Drug Dev       Date:  2017-05-02

7.  Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.

Authors:  SoJeong Yi; Tae-Eun Kim; Seo Hyun Yoon; Joo-Youn Cho; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu
Journal:  J Cardiovasc Pharmacol       Date:  2011-06       Impact factor: 3.105

8.  Quantitative model for the blood pressure-lowering interaction of valsartan and amlodipine.

Authors:  Young-A Heo; Nick Holford; Yukyung Kim; Mijeong Son; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2016-10-03       Impact factor: 4.335

9.  A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times.

Authors:  Yanfeng Wang; Yen Lin Chia; Jerry Nedelman; Horst Schran; Francois-Xavier Mahon; Mathieu Molimard
Journal:  Ther Drug Monit       Date:  2009-10       Impact factor: 3.681

10.  Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects.

Authors:  Woo Youl Kang; Sook Jin Seong; Boram Ohk; Mi-Ri Gwon; Bo Kyung Kim; Sookie La; Hyun-Ju Kim; Seungil Cho; Young-Ran Yoon; Dong Heon Yang; Hae Won Lee
Journal:  Drug Des Devel Ther       Date:  2018-03-14       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.